



Patrys Limited
ACN 123 055 363

Entitlement Issue Offer Document

**Non-renounceable pro-rata issue of shares at an issue price of 5 cents
on the basis of 1 new share for every 2 shares held on the Record Date**

THIS PAGE IS LEFT INTENTIONALLY BLANK



27 November 2013

Dear Shareholder

LETTER FROM THE CHAIRMAN

On behalf of your Directors, I ask you to carefully consider the opportunity to invest further in Patrys Limited ACN 123 055 363 (**Patrys** or **the Company**) through this pro-rata offer of new shares.

The offer provides shareholders with the right to subscribe for 1 new share for every 2 existing shares held at an issue price of 5 cents per share (**Rights Issue**). You also have the ability to apply for additional shares which will be available to the extent that other shareholders do not take up their Rights Issue shares (**Share Top Up Offer**). Under the combined Rights Issue and Share Top Up Offer, Patrys is seeking to raise up to \$12.5 million.

The structure of the Rights Issue with a Share Top Up Offer has been designed to provide the maximum opportunity to existing Patrys shareholders to subscribe for further shares in the Company, while at the same time ensuring that a sufficient amount of capital will be raised.

As announced on Monday, 11 November 2013, Onyx Pharmaceuticals Inc., a subsidiary of Amgen Inc., has agreed to fund an investigator-sponsored trial evaluating the effectiveness of Patrys' lead anti-cancer drug PAT-SM6 in combination with its leading multiple myeloma (MM) product, carfilzomib, in patients with relapsed and refractory MM.

The proceeds raised pursuant to the Rights Issue and Share Top Up Offer will be used to support the manufacturing of the product to be used in this trial, preclinical scale-up of PAT-LM1 and manufacturing to produce GMP material in preparation for clinical trial and a broad range of other activities associated with advancing Patrys' pipeline.

PAT-SM6 is currently being evaluated in a Phase I/IIa clinical trial in patients with relapsed and multi-drug resistant multiple myeloma. The trial has been ongoing for almost a year, with nine patients treated so far. The final cohort of three patients (total of 12 patients) is currently being recruited. Among those already treated, there is convincing evidence that PAT-SM6 is active in patients with end-stage disease who are resistant to other marketed therapies. In addition, two multi-resistant patients have experienced stable disease post treatment with PAT-SM6. These are highly promising results in patients that are very sick and have run out of therapeutic options. This trial should be completed by the end of the year with full data expected to be released 1Q 2014.

Your Directors believe that this is an exciting time to be involved with the Company. I ask you to read this offer document (**Offer Document**) in its entirety and, on behalf of the Patrys Board, invite you to participate.

Yours faithfully

A handwritten signature in black ink, appearing to read "John D. Read", is written over a horizontal line.

John D. Read
Chairman

1. Introduction - Patrys Limited share offers:

- **Non-renounceable Rights Issue offer**
- **Share Top Up Offer for any shortfall under the Rights Issue**

Patrys is seeking to raise capital via a non-renounceable rights issue to current shareholders. Patrys is also offering shareholders (other than Directors or their associates) the right to increase their percentage shareholding in Patrys via a share top up offer should there be any shortfall under the Rights Issue. The price of the shares to be issued under both the Rights Issue and the Share Top Up Offer will be 5 cents (**Offer Price**).

Azure Capital Limited and BBY Limited are Joint Lead Managers for the Rights Issue.

The Directors also reserve the right to place any remaining shortfall after the Share Top Up Offer in the three months after the Closing Date at an issue price not less than the Offer Price to parties other than related parties of the Company.

Under the combined Rights Issue and Share Top Up Offer, Patrys is seeking to raise up to \$12.5 million.

The structure of the Rights Issue with a Share Top Up Offer has been designed to provide the maximum opportunity to existing Patrys shareholders to subscribe for further shares in the Company, while at the same time ensuring that a sufficient amount of capital will be raised.

In section 1 of this Offer Document we have outlined the terms of the Rights Issue. Section 2 defines the terms of the Share Top Up Offer.

It is important that you should read this Offer Document in its entirety before making any investment decision, including the risk factors detailed in section 7.

2. Rights Issue Offer

2.1. Offer to eligible shareholders

The Rights Issue is being offered to all shareholders that meet the following two criteria:

- (i) the shareholder is recorded on the register of Patrys at 7.00 p.m. AEDT on 25 November 2013 (**Record Date**), and
- (ii) the shareholder resides in Australia, New Zealand or the United Kingdom,

(Eligible Shareholder(s)).

The Rights Issue is a non-renounceable pro rata rights issue, available to Eligible Shareholders, on the basis of offering for subscription 1 ordinary share for every 2 existing ordinary shares held by the shareholder on the Record Date (rounded up to the nearest whole number) and otherwise in accordance with the terms set out in this Offer Document. Details of your entitlement are contained in the attached personalised Entitlement and Acceptance Form.

You may accept for all or only part of your entitlement.

2.2. Issue price under Rights Issue

The shares issued pursuant to the Rights Issue are offered at an issue price of 5 cents per share (**Rights Issue Shares**).

2.3. Foreign shareholders

Eligible Shareholders include only those whose registered addresses are within Australia, New Zealand or the United Kingdom (**Eligible Jurisdictions**) on the Record Date.

The Rights Issue offer is not being made to shareholders with a registered address outside the Eligible Jurisdictions at the Record Date (**Excluded Shareholders**) because of the costs associated with making offers in other foreign jurisdictions.

3. Share Top Up Offer

3.1. Offer to Eligible Shareholders

Patrys will also offer Eligible Shareholders (other than the Directors or their associated entities) the right to subscribe for additional shares if they wish to do so. The Share Top Up Offer is not renounceable.

No shortfall shares will be placed to parties other than Eligible Shareholders until all applications under the Share Top Up Offer have been satisfied in full. In the event that the Share Top Up Offer is oversubscribed the shortfall will be allocated so that Eligible Shareholders will be given a priority right to subscribe for up to \$5,000 each (inclusive of their entitlement) before any of the shortfall is allocated to other Eligible Shareholders. Thereafter, the shortfall will be allocated pro-rata to the entitlements of Eligible Shareholders pursuant to the Rights Issue.

If you wish to subscribe for additional shares under the Share Top Up Offer, you need to nominate the number of additional shares that you wish to subscribe for on the attached Entitlement and Acceptance Form, or if paying by Bpay, make your payment for the total amount you wish to apply for including under the Share Top Up Offer.

3.2. Issue price under Share Top Up Offer

The issue price under the Share Top Up Offer is 5 cents (being the same as under the Rights Issue).

3.3. Foreign shareholders

Eligible Shareholders under the Share Top Up Offer include only those whose registered addresses are within the Eligible Jurisdictions on the Record Date. Due to the cost of compliance with an offer of shares in some foreign jurisdictions, the Share Top Up Offer is not available to Excluded Shareholders.

4. Use of funds raised

As announced on Monday, 11 November 2013, Onyx Pharmaceuticals Inc., a subsidiary of Amgen Inc., has agreed to fund an investigator-sponsored trial evaluating the effectiveness of Patrys' lead anti-cancer drug PAT-SM6 in combination with its leading multiple myeloma (MM) product, carfilzomib, in patients with relapsed and refractory MM.

Patrys now needs to raise funds for the manufacturing of the product to be used in this trial as well as a broad range of other activities associated with advancing the pipeline.

The proceeds raised pursuant to the Rights Issue and Share Top Up Offer will be used to support, in part, lead product clinical development, operations, business development, corporate development and working capital.

In addition to working capital, specifically, the funds will be used for:

PAT-SM6 Clinical Programme:

- i. Prepare and execute a Phase Ib/IIa clinical trial in patients with Multiple Myeloma (MM) involving a European based multi-centre trial with relapsed/refractory MM patients. PAT-SM6 will be used in combination with carfilzomib.
- ii. Manufacturing of GMP material to support the Phase Ib/IIa clinical trial.
- iii. Expand external collaboration alliances to generate additional preclinical data and intellectual property with a focus on haematological malignancies.
- iv. Fund activities related to potential partnering/out-licensing of PAT-SM6.

PAT-LM1 Preclinical Programme:

- i. Preclinical scale-up manufacturing to produce GMP material in preparation for clinical trial.
- ii. Additional preclinical work both internal and with external partners to generate additional data and intellectual property.

PAT-SC1 Out-licensing Programme:

- i. Fund activities related to the ongoing partnering/out-licensing of PAT-SC1.

PAT-NM1, PAT-SM3 Discovery Programme:

- i. Preclinical development and target discovery work.

5. Timetable

The proposed timetable* for the Rights Issue and Share Top Up Offer is as follows:

Initial announcement of Rights Issue and Share Top Up Offer, lodgement of Appendix 3B and s708AA notice.	Prior to commencement of trading on Wednesday 13 November 2013
Dispatch letters to option holders (including timetable)	Wednesday 13 November 2013
Dispatch letters to shareholders and ineligible shareholders (including timetable)	Thursday 14 November 2013
"Ex" Date (ie. date from which securities are quoted on an ex basis)	Tuesday 19 November 2013
Record Date (ie. date for determining entitlement to participate in the Rights Issue and Share Top Up Offer)	Monday 25 November 2013
Dispatch of Rights Issue and Share Top Up Offer document and personalised Entitlement and Acceptance Form	Wednesday 27 November 2013
Closing Date	Wednesday 11 December 2013
Securities quoted on a deferred settlement basis.	Thursday 12 December 2013
Company notifies ASX of under subscriptions	Monday 16 December 2013
Allotment of shares under Rights Issue and Share Top Up Offer and despatch of holding statements	Thursday 19 December 2013
Trading of shares issued under Rights Issue and Share Top Up Offer expected to commence on ASX	Friday 20 December 2013

* Note: This timetable is indicative only and subject to change. The Company reserves the right to change the dates, including the Closing Date without prior notice, subject to the Listing Rules. Any extension of the Closing Date will have a consequential effect on the anticipated date for allotment and issue of the new shares.

6. Supporting Information

6.1. Share capital structure

The total number of Patrys shares which may be issued in aggregate under the Rights Issue and the Share Top Up Offer is 269,481,089 shares.

The following table details the Company's existing share capital and details of the change in share capital following the completion of the Rights Issue and the Share Top Up Offer, assuming full subscription.

Category		Shares	Unlisted Options
Currently Issued Shares	Number	538,962,177	18,400,000 ¹ 3,735,559 ²
	Percent	66.67%	
New Shares Under Rights Issue and Share Top Up Offer	Number	269,481,089	N/A
	Percent	33.33%	
Total	Number	808,443,266	22,135,559
	Percent	100.0%	

1. Exercisable at \$0.05 on or before 30 June 2014

2. Issued under the Executive Share Option Plan. These options have various exercise prices and expiry dates.

6.2. Share trading history

The lowest and highest market sale prices of shares on the ASX during the three months prior to 13 November 2013 (the date the Rights Issue was announced to the ASX) were 2.4 cents on 28 October 2013 and 9.2 cents on 11 November 2013, respectively.

The last price for shares traded on the ASX prior to the finalisation of this Offer Document was 6 cents.

6.3. ASX quotation

Application has been made to ASX for the official quotation of the shares to be issued under the Rights Issue. If permission is not granted by ASX for the official quotation of the shares to be issued under the Rights Issue, Patrys will repay, without interest, all application monies received pursuant to the Rights Issue.

6.4. Taxation implications

The Directors do not consider it appropriate to give shareholders advice regarding the taxation consequences of subscribing for shares under this Rights Issue. Patrys, its advisers and its officers do not accept any responsibility or liability for any such taxation consequences to shareholders. As a result, shareholders should consult their professional tax adviser in connection with subscribing for shares under this Rights Issue.

6.5. Privacy

Patrys collects information about each applicant provided on an Entitlement and Acceptance Form for the purposes of processing the application and, if the application is successful, to administer the applicant's security holding in Patrys.

By submitting an Entitlement and Acceptance Form, each applicant agrees that Patrys may use the information provided by an applicant on the Entitlement and Acceptance Form for the purposes in this privacy disclosure statement and may disclose it for those purposes to the share registry, Patrys' related bodies corporate, agents, contractors and third party service providers, including mailing houses and professional advisers, and to ASX and regulatory authorities.

If an Entitlement and Acceptance Form is submitted and you do not provide the information required on the Entitlement and Acceptance Form, Patrys may not be able to accept or process your application.

An applicant has a right to gain access to the information that Patrys holds about that person subject to certain exemptions under law. A fee may be charged for access. Access requests must be made in writing to Patrys' registered office.

7. Risk factors

Investment in the Company involves risks which may be higher than the risks associated with an investment in other companies. The shares to be issued under the Rights Issue and the Share Top Up Offer carry no guarantee with respect to the payment of dividends, returns of capital or the market value of the shares.

Before deciding to participate in any of the offers detailed in this Offer Document, you should refer to announcements made by the Company to the ASX to ensure you understand the operations of the Company and appreciate the risks involved with investing in the Company. Further, you should consider the investment in the context of your individual risk profile for speculative investments, investment objectives and individual financial circumstances.

The following is a brief summary of some of the key risk factors:

7.1. Specific risks

- (a) **Innovative technological development.** The Company's product candidates are at an early stage in clinical development and need to be further tested in human clinical trials. Human clinical trials are very expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. Clinical trials of the Company's product candidates could take several years to complete. Clinical development of the Company's products may fail for a number of other reasons including lack of efficacy, toxicity, or adverse side effects. Failure can occur at any stage of the trials, requiring the Company to abandon or repeat clinical trials.
- (b) **Manufacturing / production risks.** While the Company has had success in developing a manufacturing platform for natural human antibodies that has supported activities to date, that platform has not yet been scaled up to a level commensurate with potential market requirements, and therefore there is a risk that such scale up may present technical difficulties.
- (c) **Third party collaborations and potential licensing partners.** The Company has established collaborative relationships and intends to continue to establish additional collaborative relationships to achieve its product development objectives. The Company does not have all the resources that it needs to internally develop its product candidates through full clinical development and to launch marketable products and relies on its ability to maintain and enter into collaborative and licensing relationships to achieve this objective, and relies on its collaborators to fulfil their contractual responsibilities.
- (d) **Healthcare insurers and reimbursement.** In both domestic and foreign markets, sales of products are likely to depend in part upon the availability and amounts of reimbursement from third party health care payor organisations, including government agencies, private health care insurers and other health care payors such as health maintenance organisations and self-insured employee plans. No assurance can be given that reimbursement will be provided by such payors at all or without substantial delay, or, if such reimbursement is provided, that the approved reimbursement amounts will be sufficient to enable the Company to sell products developed profitably.

- (e) **Dependence on service providers.** The Company relies upon independent third party service providers for a significant amount of its key pre-clinical, manufacturing and clinical activities. The Company therefore is exposed to the risk that any of these parties can experience problems related to operations, financial strength or other issues, which in turn could negatively impact the progress or success of the Company's product development efforts.
- (f) **Currency risk.** Revenue and expenditure in overseas jurisdictions are subject to the risk of fluctuations in foreign exchange markets. The Company carries on part of its business outside of Australia and intends to continue to do so. Accordingly, payment will be made in those countries' currencies and may exceed the budgeted expenditure if there are adverse currency fluctuations against the Australian dollar. The Company currently holds both US dollars and Euro sufficient to meet budgeted expenditure that will be incurred in those currencies through to March 2014 which provides a hedge for these foreign currency payments.
- (g) **Patent rights.** The Company heavily relies for its success on its ability to obtain and maintain patent protection for therapeutic product candidates and their respective targets. The Company owns issued and pending patent applications covering human antibodies, the production cell lines, and in some cases the associated molecular targets and platform technologies. The prospect of attaining patent protection for products such as those proposed to develop is highly uncertain and involves complex and continually evolving factual and legal questions.

7.2. General risks

- (a) **Securities investment.** Applicants should be aware that there are risks associated with any securities investment. The prices at which the Company's securities trade may be above or below the issue price, and may fluctuate in response to a number of factors.

Furthermore, the stock market, and in particular the market for biotech companies, has experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of such companies. These factors may materially affect the market price of the securities, regardless of the Company's operational performance.

- (b) **Share market conditions.** The market price of the securities may fall as well as rise and may be subject to varied and unpredictable influences on the market for securities in general and biotech stocks in particular. Neither the Company nor the Directors warrant the future performance of the Company or any return on an investment in the Company.
- (c) **General economic climate and share market conditions.** Factors such as global credit risks, inflation, currency fluctuation, interest rates and supply and demand have an impact on operating costs and stock market prices. The Company's future revenues and the market price for its listed securities may be affected by these factors which are beyond the Company's control.

7.3. Investment speculative

The above list of risk factors should not be taken as exhaustive of the risks faced by the Company or by investors in the Company. The above factors, and others not specifically referred to above, may in future materially affect the financial performance of the Company and the value of the securities offered. Potential investors should consider that an investment in the Company is speculative and should be in a position to bear the economic loss of their investment. Applicants should consult their professional adviser before deciding whether to apply for securities.

8. **Directors' interests in company securities**

The Directors' current relevant interest in shares and prospective relevant interests in shares in the Company are as follows:

	John Read	Marie Roskrow	Michael Stork ¹	Suzy Jones
Current number of shares	5,058,389	2,541,667	85,731,764	2,500,000
Entitlement to shares under the offer	2,529,195	1,270,834	42,865,882	1,250,000
Maximum number of shares after offer	7,587,584	3,812,501	128,597,646	3,750,000

1 These shares are held by Stork Holdings 2010 Ltd. The shares are held by a related trust which Michael Stork in his own right does not control.

Each of the Directors intend to take up all or part of their entitlement under the Rights Issue.

The Directors also hold the following unlisted options:

	John Read	Marie Roskrow	Michael Stork	Suzy Jones
Current number of options	700,000	375,000	300,000	-

9. **Substantial Holders' interest in Company securities**

The Company's Substantial Shareholders and the number of shares and their percentage holdings in which they have an interest as disclosed by notices received under Part 6.7 of the Corporations Act 2001 as at the date of this Offer Document are:

Name	Ordinary Shares	% Held
Stork Holdings 2010 Ltd	85,731,764	16.9
Dr. Dax Marcus Calder	32,500,000	6.4

Stork Holdings 2010 Ltd is the only person or entity who could increase their holding above 20% under the rights issue. Stork Holdings 2010 Ltd has advised the Company it will take up a total of 10,000,000 Rights Issue Shares and will not participate in the Share Top Up Offer. The maximum voting power of Stork Holdings 2010 Ltd after the Rights Issue will therefore be 17.4%.

As noted in section 7 Stork Holding 2010 Ltd is a Company related to Michael Stork.

10. **Acceptance**

A personalised Entitlement and Acceptance Form and a reply-paid envelope is enclosed with this Offer Document. The Entitlement and Acceptance Form shows the number of Rights Issue Shares to which you are entitled. Fractional entitlements have been rounded up.

10.1. **If you wish to take up all or part of your entitlement**

You may accept part or all of your entitlement (and apply for additional shares – see 9.2 below) by completing the Entitlement and Acceptance Form and returning it with subscription monies in accordance with the instructions set out on the reverse side of the Entitlement and Acceptance Form prior to the Closing Date.

10.2. If you wish to apply for additional shares under the Share Top Up Offer

Eligible Shareholders may, in addition to taking up all of the entitlement, apply for additional shares under the Share Top Up Offer. Any shortfall will first be applied to ensure all Eligible Shareholders who have applied for shares up to a value of \$5,000 (inclusive of their entitlement) will receive shares to at least that value. If the shortfall is not sufficient to allow this to occur, applications for additional shares will be scaled back on a pro rata basis.

No additional shares will be issued under the Share Top Up Offer which will result in a shareholder increasing their voting power in the Company above 20%.

Should you wish to apply for shortfall shares under the Share Top Up Offer, application must be made in accordance with the instructions referred to in the Entitlement and Acceptance Form. Please read the instructions carefully.

10.3. How to apply for shares using the Entitlement and Acceptance Form

If you wish to take up all or part of your entitlement under the Rights Issue and the Share Top Up Offer, the Entitlement and Acceptance Form should be completed in accordance with the instructions in the form and sent to:

**Patrys Limited
C/- Computershare Investor Services Pty Limited
GPO Box 505
Melbourne, Victoria 3001
Australia**

Applications must be received no later than 5.00 p.m. AEDT on the Closing Date of 11 December 2013.

Payments will only be accepted in Australian currency and as follows:

- BPAY. Those that use BPAY **will not need to** return the Entitlement and Acceptance Form but will need to provide their holder identification number (HIN) as a payment reference;
- Bank cheque drawn on and redeemable at any Australian bank; or
- Personal cheque drawn on and redeemable at any Australian bank.

Cheques or bank cheques should be marked "not negotiable" and made payable to Patrys Limited.

By applying for shares under the Rights Issue and the Share Top Up Offer, an Eligible Shareholder is taken to:

1. agree to be bound by the terms and conditions set out in this Offer Document and the Entitlement and Acceptance Form;
2. authorise Patrys to place the Eligible Shareholder's name on Patrys' Register in respect of the shares taken up under the offer(s); and
3. agree to be bound by Patrys' Constitution.

To the extent you decide not to accept all or part of your entitlement, or fail to do so by the Closing Date, your rights to participate in the Rights Issue and Share Top Up Offer will lapse and your percentage shareholding in the Company will be diluted.

10.4. If you do not wish to take up your entitlement

If you do not wish to take up any part of your entitlement under the Rights Issue or the Share Top Up Offer, no action is required.

The number of shares you hold will not be affected should you chose not to accept any part of your entitlement, however your percentage holding in the capital of Patrys will be diluted.

11. Allotment and ranking

11.1. Allotment

The shares which are the subject of the Right Issue and the Share Top Up Offer will be allotted and issued with holding statements dispatched, in accordance with the Timetable detailed in section 4. It is expected that shares will be allotted and that shareholder statements will be dispatched on 19 December 2013.

11.2. Ranking

Shares issued pursuant to the Rights Issue and the Share Top Up Offer will rank equally with all existing ordinary shares on issue.

Further details of the rights and liabilities attaching to ordinary shares are set out in the Company's constitution, a copy of which is available for inspection at the Company's registered offices during normal business hours and can also be found on the Company's website at www.patrys.com/about-us/patrys-corporate-governance.

The Company has made application to the ASX for quotation of the Rights Issue Shares.

12. Further enquiries

You should consult your own stockbroker, solicitor, accountant or other professional adviser before deciding whether or not to participate in the Rights Issue or the Share Top Up Offer.

If you are beneficially entitled to Patrys shares and those shares are held on your behalf by a nominee or custodian you should direct any enquiries to your nominee or custodian.

Enquires in relation to the Rights Issue or Patrys generally can be made to the Company Secretary by telephone on +61 (0)3 9670 3273 or by email to info@patrys.com. Information may also be obtained by visiting the Company's website: www.patrys.com.

For all enquiries:

Phone:



(within Australia) (03) 9670 3273

(outside Australia) +61 3 9670 3273

└ 000001 000 PAB
MR SAM SAMPLE
123 SAMPLE STREET
SAMPLETOWN VIC 3000

Make your payment:



See over for details of the Offer and how to make your payment

Non-Renounceable Rights Issue — Entitlement and Acceptance Form

 **Your payment must be received by 5.00pm (AEDT) on Wednesday, 11 December 2013**

This is an important document that requires your immediate attention. It can only be used in relation to the shareholding represented by the details printed overleaf. If you are in doubt about how to deal with this form, please contact your financial or other professional adviser.

Step 1: Registration Name & Offer Details

Please check the details provided and update your address via www.investorcentre.com if any of the details are incorrect.

If you have a CHESS sponsored holding, please contact your Controlling Participant to notify a change of address.

Step 2: Entitlement Taken Up

You can apply to accept either all or part of your Entitlement. Enter overleaf the number of new shares you wish to accept from your Entitlement and the amount of payment for those shares.

Step 3: Top Up Shares Applied for

Enter overleaf, the number of Top Up shares you wish to apply for (if any) and the amount of payment for those shares.

Any shortfall will first be applied to ensure all Eligible Shareholders who have applied for shares up to a value of \$5,000 (inclusive of their entitlement) will receive shares to at least that value. If the shortfall is not sufficient to allow this to occur, applications for additional shares will be scaled back on a pro rata basis.

Step 4: Make Your Payment

Choose one of the payment methods shown below.

BPAY®: See overleaf. Do not return the slip with BPAY payment.

By Mail: Complete the reverse side of this payment slip and detach and return with your payment. Make your cheque or bank draft payable in Australian dollars to **"Patrys Limited"**. The cheque must be drawn from an Australian bank. Cash is not accepted.

Payment will be processed on the day of receipt and as such, sufficient cleared funds must be held in your account as cheques received may not be re-presented and may result in your Application being rejected. Paperclip (do not staple) your cheque(s) to the slip below as indicated. Receipts will not be forwarded. Funds cannot be debited directly from your account.

Entering your contact details is not compulsory, but will assist us if we need to contact you.

By making your payment you confirm that you agree to all of the terms and conditions as detailed in the Offer Document dated 27 November 2013.

Turn over for details of the Offer →

Entitlement and Acceptance Form

X 9999999991

I ND

STEP 1

Registration Name & Offer Details

Registration Name: MR SAM SAMPLE
123 SAMPLE STREET
SAMPLETOWN VIC 3000

For your security keep your SRN/
HIN confidential.

Entitlement No: 12345678

Offer Details: Existing shares entitled to participate as at
7.00pm (AEDT) on Monday, 25 November 2013:

4,000

Entitlement to new shares
on a 1 for 2 basis:

1

Amount payable on acceptance
at \$0.05 per share:

\$0.01

STEP 4

Make Your Payment



Billers Code: 227504
Ref No: 1234 5678 9123 4567 89

Pay by Mail:



Make your cheque, money order or bank draft payable to "Patrys Limited".
Return your cheque with the below slip to:

Computershare Investor Services Pty Limited
GPO BOX 505 Melbourne Victoria 3001 Australia

Contact your financial institution to make your
payment from your cheque or savings
account.

Lodgement of Acceptance

If you are applying for shares and your payment is being made by BPAY®, you do not need to return the slip below. Your payment must be received by no later than 5:00pm (AEDT) on Wednesday, 11 December 2013. Applicants should be aware that their own financial institution may implement earlier cut off times with regards to electronic payment, and should therefore take this into consideration when making payment. Neither Computershare Investor Services Pty Limited (CIS) nor Patrys Limited accepts any responsibility for loss incurred through incorrectly completed BPAY® payments. It is the responsibility of the applicant to ensure that funds submitted through BPAY® are received by this time.

If you are paying by cheque, bank draft or money order the slip below must be received by CIS by no later than 5:00pm (AEDT) on Wednesday, 11 December 2013. You should allow sufficient time for this to occur. A reply paid envelope is enclosed for shareholders in Australia. Other Eligible Shareholders will need to affix the appropriate postage. Return the slip below with cheque attached. Neither CIS nor the Patrys Limited accepts any responsibility if you lodge the slip below at any other address or by any other means.

Privacy Statement

Personal information is collected on this form by Computershare Investor Services Pty Limited (CIS) as registrar for the securities issuer (the issuer), for the purpose of maintaining registers of shareholders, facilitating distribution payments and other corporate actions and communications. Your personal information may be disclosed to our related bodies corporate, to external service companies such as print or mail service providers, or as otherwise permitted by law. If you would like details of your personal information held by CIS, or you would like to correct information that is inaccurate, incorrect or out of date, please contact CIS. In accordance with the Corporations Act 2001, you may be sent material (including marketing material) approved by the issuer in addition to general corporate communications. You may elect not to receive marketing material by contacting CIS using the details provided above or email privacy@computershare.com.au

Detach here

Acceptance Payment Details

STEP 2

Entitlement taken up:

--	--	--	--	--	--	--	--	--	--

STEP 3

Number of Top Up shares
applied for:

--	--	--	--	--	--	--	--	--	--

Amount enclosed at \$0.05 per
new share:

A\$

--	--	--	--	--	--	--	--	--	--

 .

--	--

Payment must be received by 5.00pm (AEDT) on Wednesday, 11 December 2013

Contact Details

Contact
Name

Daytime

Telephone

Cheque Details

Drawer	Cheque Number	BSB Number	Account Number	Amount of Cheque
				A\$



Entitlement No: 12345678

MR SAM SAMPLE
123 SAMPLE STREET
SAMPLETOWN VIC 3000

123456789123456789+0000000001-3051+14